MA29169B1 - Formulations intraveineuses d'inhibiteurs de la pde-5 - Google Patents

Formulations intraveineuses d'inhibiteurs de la pde-5

Info

Publication number
MA29169B1
MA29169B1 MA30102A MA30102A MA29169B1 MA 29169 B1 MA29169 B1 MA 29169B1 MA 30102 A MA30102 A MA 30102A MA 30102 A MA30102 A MA 30102A MA 29169 B1 MA29169 B1 MA 29169B1
Authority
MA
Morocco
Prior art keywords
pde
inhibitors
intravenous formulations
intravenous
formulations
Prior art date
Application number
MA30102A
Other languages
English (en)
Inventor
Peter Serno
Helmut Haning
Frank Reetz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA29169B1 publication Critical patent/MA29169B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UN NOUVELLE FORME PHARMACEUTIQUE D'INHIBITEURS DE PDE POUR ADMINISTRATION INTRAVEINEUSE ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES.
MA30102A 2005-01-15 2007-07-26 Formulations intraveineuses d'inhibiteurs de la pde-5 MA29169B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005001989A DE102005001989A1 (de) 2005-01-15 2005-01-15 Intravenöse Formulierungen von PDE-Inhibitoren

Publications (1)

Publication Number Publication Date
MA29169B1 true MA29169B1 (fr) 2008-01-02

Family

ID=36250941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30102A MA29169B1 (fr) 2005-01-15 2007-07-26 Formulations intraveineuses d'inhibiteurs de la pde-5

Country Status (17)

Country Link
US (1) US20080280914A1 (fr)
EP (1) EP1843772A1 (fr)
JP (1) JP2008526907A (fr)
KR (1) KR20070098911A (fr)
CN (1) CN101102774A (fr)
AU (1) AU2006205908A1 (fr)
BR (1) BRPI0606322A2 (fr)
CA (1) CA2594709A1 (fr)
DE (1) DE102005001989A1 (fr)
IL (1) IL184569A0 (fr)
MA (1) MA29169B1 (fr)
MX (1) MX2007008442A (fr)
NO (1) NO20074109L (fr)
RU (1) RU2007130997A (fr)
SG (1) SG158863A1 (fr)
WO (1) WO2006074872A1 (fr)
ZA (1) ZA200705736B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4879977B2 (ja) 2005-06-10 2012-02-22 ドン・ア・ファーム・カンパニー・リミテッド ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤
DE102007004144A1 (de) 2007-01-22 2008-07-24 Androtec Gmbh Lichtstrahlempfänger mit Störsignalunterdrückung
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
WO2011162320A1 (fr) * 2010-06-23 2011-12-29 国立大学法人九州大学 Combinaison d'egcg ou egcg méthylé et un inhibiteur de pde
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN105025900B (zh) * 2012-12-04 2018-11-02 株式会社阿丽浱欧 包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
CN103479570A (zh) * 2013-09-27 2014-01-01 南京奇鹤医药科技有限公司 一种伐地那非注射液的制备方法
AU2019319004A1 (en) * 2018-08-06 2021-03-25 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
BR112021009578A2 (pt) 2018-12-06 2021-08-17 Glaxosmithkline Intellectual Property Development Limited formulação farmacêutica
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
WO2021095945A1 (fr) * 2019-11-14 2021-05-20 순천향대학교 산학협력단 Utilisation de sildénafil et d'inhibiteurs rock pour traiter l'accident vasculaire cérébral ou les séquelles d'un accident vasculaire cérébral
EP4100014B1 (fr) * 2020-02-05 2024-01-03 Nicox S.A. Compositions pour le traitement du glaucome et de l'hypertension oculaire
TW202233623A (zh) * 2020-11-09 2022-09-01 南韓商日東製藥股份有限公司 氮氧化物供與的pde-5及/或pde-6抑制劑化合物及其用途
CN115969781A (zh) * 2023-01-09 2023-04-18 北京悦康科创医药科技股份有限公司 一种枸橼酸爱地那非注射剂及其制备方法和用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2036070A (en) * 1932-03-18 1936-03-31 Westinghouse X Ray Co Inc X-ray exposure timer
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (fr) * 1963-01-16
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
WO1991015194A1 (fr) * 1990-04-11 1991-10-17 The Upjohn Company Masquage du gout de l'ibuprofene par enrobage en lit fluidise
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
PT1049695E (pt) * 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (fr) * 1999-10-11 2005-07-12 Pfizer Inc. Composes pharmaceutiques actifs
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
KR20020062770A (ko) * 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
CN1630532A (zh) * 2000-04-19 2005-06-22 约翰斯霍普金斯大学 预防和治疗胃肠疾病的方法
ATE266407T1 (de) * 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
KR100750554B1 (ko) * 2001-02-15 2007-08-20 다나베 세이야꾸 가부시키가이샤 구강 내 속붕괴성 정제
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
PL363679A1 (en) * 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil

Also Published As

Publication number Publication date
JP2008526907A (ja) 2008-07-24
ZA200705736B (en) 2008-12-31
SG158863A1 (en) 2010-02-26
EP1843772A1 (fr) 2007-10-17
RU2007130997A (ru) 2009-02-20
NO20074109L (no) 2007-08-08
US20080280914A1 (en) 2008-11-13
AU2006205908A1 (en) 2006-07-20
BRPI0606322A2 (pt) 2009-06-16
CA2594709A1 (fr) 2006-07-20
DE102005001989A1 (de) 2006-07-20
CN101102774A (zh) 2008-01-09
MX2007008442A (es) 2007-09-06
WO2006074872A1 (fr) 2006-07-20
KR20070098911A (ko) 2007-10-05
IL184569A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA30041B1 (fr) Immunoglobulines
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
TNSN00169A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TW200700392A (en) Novel compounds
FIC20130042I1 (fi) Fampridiini tai sen suola tai solvaatti
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
MA32686B1 (fr) Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
HUP0400368A2 (hu) Oxitocin agonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk szexuális zavarok kezelésére